Potential options for reducing cardiotoxicity of anthracyclines

What are the potential options for reducing cardiotoxicity of anthracyclines?

Anthracyclines are an important group of medications useful in the treatment of solid tumours and hematological malignancies. An important limitation is their potential cardiotoxicity which can cause heart failure at varying time intervals, even decades later. Some methods which have been used to prevent cardiotoxicity are longer infusion times, use of liposomal preparations, dexrazoxane, beta blockers and renin-angiotensin system inhibitors, all with different success rates. These strategies have not been universally accepted as useful modalities.